Portage Biotech (PRTG) Competitors

Elevation Oncology (NASDAQ:ELEV) and Portage Biotech (NASDAQ:PRTG) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, media sentiment, risk, analyst recommendations, earnings, community ranking, institutional ownership, valuation and dividends.

Is ELEV or PRTG more profitable?

Elevation Oncology's return on equity of -59.73% beat Portage Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elevation Oncology	N/A	-59.73%	-40.05%
Portage Biotech	N/A	-342.34%	-196.47%

Which has more risk & volatility, ELEV or PRTG?

Elevation Oncology has a beta of 1.37, suggesting that its stock price is 37% more volatile than the S&P 500. Comparatively, Portage Biotech has a beta of 1.29, suggesting that its stock price is 29% more volatile than the S&P 500.

Does the media prefer ELEV or PRTG?

In the previous week, Elevation Oncology had 7 more articles in the media than Portage Biotech. MarketBeat recorded 14 mentions for Elevation Oncology and 7 mentions for Portage Biotech. Portage Biotech's average media sentiment score of 0.69 beat Elevation Oncology's score of 0.03 indicating that Portage Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Elevation Oncology	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral
Portage Biotech	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has better valuation and earnings, ELEV or PRTG?

Elevation Oncology is trading at a lower price-to-earnings ratio than Portage Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elevation Oncology	N/A	N/A	-$45.70M	-$0.81	-0.32
Portage Biotech	N/A	N/A	-$75.34M	-$41.65	-0.23

Do analysts prefer ELEV or PRTG?

Elevation Oncology presently has a consensus target price of $3.39, indicating a potential upside of 1,202.20%. Given Elevation Oncology's stronger consensus rating and higher possible upside, equities research analysts plainly believe Elevation Oncology is more favorable than Portage Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elevation Oncology	0 Sell rating(s)	7 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.30
Portage Biotech	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Does the MarketBeat Community believe in ELEV or PRTG?

Elevation Oncology received 26 more outperform votes than Portage Biotech when rated by MarketBeat users. Likewise, 66.10% of users gave Elevation Oncology an outperform vote while only 59.09% of users gave Portage Biotech an outperform vote.

Company	Underperform	Outperform
Elevation Oncology	Outperform Votes 39 66.10%	Underperform Votes 20 33.90%
Portage Biotech	Outperform Votes 13 59.09%	Underperform Votes 9 40.91%

Do institutionals & insiders have more ownership in ELEV or PRTG?

83.7% of Elevation Oncology shares are owned by institutional investors. Comparatively, 13.4% of Portage Biotech shares are owned by institutional investors. 8.1% of Elevation Oncology shares are owned by company insiders. Comparatively, 42.1% of Portage Biotech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Elevation Oncology beats Portage Biotech on 12 of the 15 factors compared between the two stocks.